TRIUMPH-3 (NCT05882045) will investigate change in bodyweight in people with overweight/obesity and cardiovascular disease, and TRIUMPH-4 (NCT05931367) will assess change in WOMAC score and bodyweight in individuals with overweight/obesity and knee OA
Migraine is a complex neurological disease that involves inflammation, changes in pain signaling, and a range of other complications, explains Suraj Malhan, DO, a headache and facial pain neurologist at RWJBarnabas Health, Monmouth Medical Center
Report any suspected side effects to medicines via the MHRA Yellow Card Scheme at yellowcard.mhra.gov.uk or via the Yellow Card app
GLP-1 drugs may be discussed as an off-label option for people who: Have moderate to severe HS Live with obesity or metabolic dysfunction Have not achieved adequate control with standard treatments Are already candidates for GLP-1 therapy for metabolic reasons Any decision to use GLP-1 medication should involve careful medical supervision and shared decision-making
Pancreatitis: Some reports have linked GLP-1 receptor agonists, including semaglutide, to pancreatitis, although such cases are rare
For those with a type 2 diabetes diagnosis, Mounjaro helps manage blood sugar levels, requiring verified medical evidence to be prescribed
